Investors & Media

News

  • Item Type:
  • Year:
  • 29 Oct. 2013

    Kamada Reports Third Quarter 2013 Financial Results

    European Phase 2/3 trial of inhaled AAT for AATD to complete by year-end
    Adjusting 2013 revenue guidance; product sales from Baxter remain on track
    Conference call begins today at 8:30 a.m. Eastern time

  • 21 Oct. 2013

    Kamada to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, October 29, 2013

    Kamada management will host an investment community conference call on Tuesday, October 29, 2013 beginning at 8:30 a.m. Eastern time

  • 4 Sep. 2013

    Kamada to Present at September Investment Conferences

    NESS ZIONA, Israel (September 4, 2013) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Gil Efron, Kamada's Chief Financial Officer, will deliver a corporate overview at two upcoming investment conferences in New York City. Rodman and Renshaw's 15th Annual Global Healthcare Conference taking place from […]

  • 1 Aug. 2013

    Kamada Reports Second Quarter 2013 Financial Results

    Net Income of $1 million and Adjusted EBITDA of $4 million; Phase 3 clinical trial of Inhaled AAT for AATD in EU on track to complete this year; Conference Call Begins Today at 10:00 a.m. Eastern Time.

  • 10 Jul. 2013

    Study demonstrating pancreatic islet xenograft survival with kamada’s AAT published in peer-reviewed publication

    This study examined transplant survival of pancreatic islets originating in other (xeno) species donors. in combination with Glassia, there was a significant time extension in graft acceptance and a higher rate of graft acceptance compared with groups that did not receive Glassia.

  • 24 Jun. 2013

    Kamada granted two key patents

    the Company was granted two key patents related to its novel Alpha-1 Antitrypsin (AAT) product to treat respiratory diseases.

  • 31 May. 2013

    NASDAQ Welcomes Kamada Ltd. to The NASDAQ Stock Market

    The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that trading of Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company, commenced on The NASDAQ Stock Market on Friday, May 31, 2013.

  • 31 May. 2013

    Kamada announces pricing of initial public offering

    Kamada Ltd. today announced the pricing of its initial public offering in the United States of 5,582,636 ordinary shares at a price to the public of $9.25 per ordinary share.

  • 16 May. 2013

    Kamada announces extension to strategic agreement with Baxter

    Total revenue from sales of Glassia in USA is expected to grow: minimum revenues of approximately $165 million

  • 6 May. 2013

    Kamada announces results for the first quarter of 2013

    David Tsur, CEO said: “ We continue to implement successfully our strategic plan that includes strong growth in our Proprietary Products segment, mainly based on sales of AAT products in the U.S. and other countries, including commencing sales of our inhaled product in Europe, U.S. and other markets in the midterm, along with improving our margins. The first quarter of this year supports this trend and we are confident in our ability to meet our revenues forecast for 2013, which is based on orders from Baxter for the second half of 2013.”